Skip to main content
. Author manuscript; available in PMC: 2019 Jun 15.
Published in final edited form as: Clin Cancer Res. 2018 Mar 13;24(12):2740–2748. doi: 10.1158/1078-0432.CCR-17-3796

Figure 3. Biomarker response and clinical correlation after neoadjuvant therapy with AZD1775 alone or in combination with chemotherapy.

Figure 3

Biomarker response as demonstrated by IF (left panels) and quantified IHC data as % cells stained (right panels) for (A) Y15-Cdk, (B) CC3, and (C) pRPA32 in biopsies pre-treatment (sample “A”), post-AZD alone (sample “B”), and post-AZD plus cisplatin plus docetaxel (sample “C”). (D) Fold changes in biomarkers Y15-Cdk, CC3, pRPA32, γH2AX, and pHH3 post-AZD alone (black bars) and post-AZD plus cisplatin/docetaxel (white bars), after subdividing into clinical responders (“R”) and non-responders (“NR”).